Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors

James Newman; Nagashree Seetharamu; Muhammad Wasif Saif

Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors

Cancer Med J. 2020 Dec;3(Suppl 2):17-21. Epub 2020 Nov 19.

Authors

James Newman¹, Nagashree Seetharamu¹, Muhammad Wasif Saif¹

Affiliation

¹ Northwell Health Cancer Institute, Lake Success, NY, USA.

PMID: 33377136
PMCID: PMC7769129

No abstract available

Keywords: Cancer; Immune checkpoint inhibitors (ICIs); Microsatellite instability-high (MSI-H); Microsatellite stable (MSS); POLD1; POLE; Tumor mutational burden (TMB).

Grants and funding

UG1 CA189850/CA/NCI NIH HHS/United States